Novanta 경영진
경영진 기준 점검 4/4
Novanta CEO는 Matthijs Glastra, Sep2016 에 임명되었습니다 의 임기는 9.67 년입니다. 총 연간 보상은 $10.04M, 8.6% 급여 및 91.4% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $16.66M 가치에 해당하는 회사 주식의 0.29% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 3.3 년과 5 년입니다.
핵심 정보
Matthijs Glastra
최고경영자
US$10.0m
총 보수
| CEO 급여 비율 | 8.59% |
| CEO 재임 기간 | 9.7yrs |
| CEO 지분 보유율 | 0.3% |
| 경영진 평균 재임 기간 | 3.3yrs |
| 이사회 평균 재임 기간 | 5yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Apr 19
NOVT: Future Earnings Power Will Rely On Executing Stronger Margins
Narrative update on Novanta The consensus analyst price target for Novanta has been raised by $12 to $150. Analysts cite updated models after Q4 results that indicate potential for stronger sales and margin performance.내러티브 업데이트 • Apr 05
NOVT: Future Earnings Power Will Rely On Accelerating Sales And Margins
Analysts have trimmed their fair value estimate for Novanta from $160 to $157, reflecting a slightly higher discount rate and a modestly lower future P/E assumption, while still pointing to expectations for improving sales and margins after recent model updates. Analyst Commentary Bullish Takeaways Bullish analysts see room for the shares to move toward their updated fair value range, supported by model revisions that assume improving sales trends and margin recovery after recent results.내러티브 업데이트 • Mar 22
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their price target on Novanta to $150 from $138, citing updated Q4 models that suggest the company may be positioned for faster sales growth and margin expansion. Analyst Commentary Bullish Takeaways Bullish analysts point to the raised price target to $150 as a sign that updated Q4 assumptions support a higher valuation range for the shares.내러티브 업데이트 • Mar 06
NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their fair value estimate for Novanta to $160 from $154, supported by updated models that reflect expectations for accelerating sales and margins following recent Q4 results and a higher Street price target of $150 from $138. Analyst Commentary Recent commentary points to a more constructive view on Novanta following its Q4 results, with updated models feeding into a higher fair value framework and a Street price target of $150.내러티브 업데이트 • Feb 20
NOVT: Stable Outlook Will Rely On Steady Margins And Earnings Multiple
Narrative Update: Novanta Analyst Price Target The analyst price target for Novanta is unchanged at $154, as analysts keep their assumptions for fair value, discount rate, revenue growth, profit margin and future P/E essentially steady. Valuation Changes Fair Value: $154.00 remains effectively unchanged compared with the prior estimate of $154.내러티브 업데이트 • Feb 06
NOVT: Equity Units Offering Will Support Balance Sheet And Future Deals
Analysts have nudged their price target on Novanta slightly higher to reflect modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions, framing the move as fine tuning rather than a major reset in expectations. What's in the News Novanta plans to look for acquisitions and investments, signaling an interest in adding to its portfolio of businesses (Key Developments).내러티브 업데이트 • Jan 22
NOVT: Equity Units And Share Repurchases Will Support Balance Sheet And Future Deals
Analysts now keep their price target for Novanta effectively unchanged at about $154.00. They point to steady assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of their view.내러티브 업데이트 • Jan 08
NOVT: Equity Units Offering Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their fair value estimate for Novanta at approximately $154. They cite only marginal adjustments to the discount rate, long term revenue growth, profit margin assumptions, and future P/E, which do not materially change their overall outlook.내러티브 업데이트 • Dec 24
NOVT: New Equity Raise Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their price target for Novanta at approximately $154 per share. This reflects a steady outlook, as incremental adjustments to discount rate assumptions and long term growth and profitability estimates are viewed as too minor to warrant a change in fair value.내러티브 업데이트 • Dec 10
NOVT: Expanded Equity Offering And Buybacks Will Drive Long Term Shareholder Value
Analysts have nudged their price target for Novanta slightly higher to align with its updated fair value of $154.00, reflecting modestly stronger confidence in the company’s steady growth and margin profile. What's in the News Novanta completed a $550 million composite tangible equity units offering, issuing 11 million units priced at $50 each, with a $1.375 discount per unit (Key Developments).내러티브 업데이트 • Nov 26
NOVT: Expanded Buyback Authorization Will Increase Shareholder Value Going Forward
Narrative Update on Novanta: Analyst Price Target Change Analysts have maintained Novanta's fair value estimate at $154. They cited improved profitability metrics, which offset slight adjustments in the discount rate and growth projections.내러티브 업데이트 • Nov 10
NOVT: Equity Buyback Expansion And Profit Margin Gains Will Drive Upside
Analysts have raised their fair value estimate for Novanta from $141.50 to $154.00 per share, citing expectations for stronger future revenue growth and improved profit margins, even though the discount rate is slightly higher. What's in the News Novanta Inc.분석 기사 • Oct 28
Novanta Inc. (NASDAQ:NOVT) Looks Just Right With A 30% Price Jump
Novanta Inc. ( NASDAQ:NOVT ) shares have had a really impressive month, gaining 30% after a shaky period beforehand...분석 기사 • Oct 07
Is Now The Time To Look At Buying Novanta Inc. (NASDAQ:NOVT)?
Novanta Inc. ( NASDAQ:NOVT ), is not the largest company out there, but it received a lot of attention from a...Seeking Alpha • Sep 29
Novanta: The Solution To Elevated Expectations Is Lower Prices
Summary Novanta Inc. remains a trusted technology partner for OEMs, but recent growth has been modest and organic performance underwhelming. Despite a strong track record and niche positioning, Novanta trades at a demanding 30x earnings multiple, currently posting quite flattish growth. Recent results show minimal sales and earnings growth, while NOVT leverage is set to rise due to a $200 million buyback program. I remain on the sidelines, seeking a lower entry point and a higher earnings yield to justify NOVT stock's premium and ensure a margin of safety. Read the full article on Seeking Alpha분석 기사 • Sep 13
Novanta's (NASDAQ:NOVT) Returns Have Hit A Wall
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Ideally, a business will show two...내러티브 업데이트 • Sep 05
Robotics And Healthcare Demand Will Expand Market Opportunities
Novanta’s fair value outlook remains unchanged, as both the discount rate and future P/E shifted only marginally, leaving the consensus analyst price target steady at $141.50. What's in the News Novanta projects third quarter 2025 GAAP revenue of $244 million to $247 million and full year 2025 GAAP revenue of $970 million to $985 million.분석 기사 • Aug 29
Novanta Inc.'s (NASDAQ:NOVT) Share Price Matching Investor Opinion
With a price-to-earnings (or "P/E") ratio of 69.2x Novanta Inc. ( NASDAQ:NOVT ) may be sending very bearish signals at...분석 기사 • Jun 16
Are Novanta Inc. (NASDAQ:NOVT) Investors Paying Above The Intrinsic Value?
Key Insights The projected fair value for Novanta is US$95.22 based on 2 Stage Free Cash Flow to Equity Novanta is...분석 기사 • May 20
Returns At Novanta (NASDAQ:NOVT) Appear To Be Weighed Down
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Seeking Alpha • Apr 06
Novanta: A Trusted Yet Premium Technology Partner
Summary Novanta has shown solid growth over the past decade, but growth has been a bit sluggish in recent years. The company is a key technology partner for global OEMs, with balanced revenue from advanced industrial and medical applications, boasting strong EBITDA margins. Despite a recent acquisition and increased sales, competitive dynamics, and macroeconomic challenges have pressured growth; shares are now trading at a lower, yet still premium, multiple. With debt reduced and growth returning, shares deserve a premium, but need to fall below $100 for a more attractive valuation. Read the full article on Seeking AlphaSeeking Alpha • Jan 01
Novanta: Delayed Recovery And Prolonged Struggles Ahead, Downgrade To Sell
Summary Novanta's Q3 results show revenue growth but a decline in gross margin and shipment deferrals, indicating prolonged challenges. Macroeconomic pressures, including weak demand and high interest rates, are hindering recovery in the life sciences sector. The company's book-to-bill ratio below 1 signals weakening demand, and its high debt levels add to the risk. Novanta’s valuation is too high given its low growth prospects, especially compared to more promising peers. As a result of these factors, Novanta is downgraded from a hold to a sell, as its current price does not justify the risks. Read the full article on Seeking AlphaSeeking Alpha • Sep 02
Novanta Inc.: Overpriced In A Weak Demand Market. Here's Why It's A Hold
Summary Novanta Inc. is a leading tech provider facing macroeconomic headwinds and a soft demand climate, which have pressured its revenue and profitability. Despite strong fundamentals and a solid market position, its current high valuation makes it a risky investment. NOVT has managed modest revenue growth but struggles with significant inflationary challenges. For now, a Hold rating is recommended as the stock's valuation does not align with its performance amidst ongoing market uncertainties. Read the full article on Seeking Alpha
새로운 내러티브 • Aug 28
Innovative Medical Devices And Tactical Acquisitions Poised To Accelerate Company Growth
Focusing on medical devices with new products might significantly boost future revenue through innovation, aiming for notable revenue from new launches by 2025.CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Apr 03 2026 | n/a | n/a | US$54m |
| Dec 31 2025 | US$10m | US$863k | US$54m |
| Sep 26 2025 | n/a | n/a | US$53m |
| Jun 27 2025 | n/a | n/a | US$61m |
| Mar 28 2025 | n/a | n/a | US$71m |
| Dec 31 2024 | US$9m | US$826k | US$64m |
| Sep 27 2024 | n/a | n/a | US$60m |
| Jun 28 2024 | n/a | n/a | US$62m |
| Mar 29 2024 | n/a | n/a | US$69m |
| Dec 31 2023 | US$8m | US$784k | US$73m |
| Sep 29 2023 | n/a | n/a | US$76m |
| Jun 30 2023 | n/a | n/a | US$77m |
| Mar 31 2023 | n/a | n/a | US$73m |
| Dec 31 2022 | US$7m | US$731k | US$74m |
| Sep 30 2022 | n/a | n/a | US$73m |
| Jul 01 2022 | n/a | n/a | US$64m |
| Apr 01 2022 | n/a | n/a | US$58m |
| Dec 31 2021 | US$12m | US$690k | US$50m |
| Oct 01 2021 | n/a | n/a | US$49m |
| Jul 02 2021 | n/a | n/a | US$44m |
| Apr 02 2021 | n/a | n/a | US$44m |
| Dec 31 2020 | US$5m | US$625k | US$45m |
| Oct 02 2020 | n/a | n/a | US$41m |
| Jul 03 2020 | n/a | n/a | US$42m |
| Apr 03 2020 | n/a | n/a | US$40m |
| Dec 31 2019 | US$4m | US$640k | US$41m |
보상 대 시장: Matthijs의 총 보수(USD10.04M)는 US 시장에서 비슷한 규모 기업의 평균(USD8.46M) 수준입니다.
보상과 수익: Matthijs의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Matthijs Glastra (56 yo)
9.7yrs
재임 기간
US$10,042,292
보수
Mr. Matthijs Glastra serves as Independent Director at IDEX Corporation from February 21, 2025. He has been the Chief Executive Officer and Director of Novanta Inc. since September 1, 2016 and serves as it...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.7yrs | US$10.04m | 0.29% $ 16.7m | |
| Chief Financial Officer | 15.2yrs | US$4.76m | 0.37% $ 21.1m | |
| General Counsel & Corporate Secretary | less than a year | US$237.83k | 데이터 없음 | |
| Co-Chief Operating Officer of Automation Enabling Technologies | 4.1yrs | US$2.26m | 0.045% $ 2.6m | |
| Co-Chief Operating Officer of Medical Solutions | 1.3yrs | US$3.94m | 0.0059% $ 333.9k | |
| Chief Accounting Officer & Corporate Controller | 1.8yrs | 데이터 없음 | 0.025% $ 1.4m | |
| Corporate Finance Leader & IR | no data | 데이터 없음 | 데이터 없음 | |
| Chief Information Officer & Chief Information Security Officer | 5.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Corporate Development | 2.5yrs | 데이터 없음 | 데이터 없음 | |
| Chief Human Resources Officer | 1yr | 데이터 없음 | 데이터 없음 | |
| Group President of Medical Solutions | 8.1yrs | 데이터 없음 | 데이터 없음 |
3.3yrs
평균 재임 기간
52.5yo
평균 나이
경험이 풍부한 관리: NOVT의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Chairman of the Board | 9.7yrs | US$10.04m | 0.29% $ 16.7m | |
| Chairman Emeritus | 5yrs | US$233.48k | 데이터 없음 | |
| Independent Director | less than a year | US$45.38k | 데이터 없음 | |
| Independent Director | 1.8yrs | US$267.48k | 0.0053% $ 302.2k | |
| Independent Director | 3.9yrs | US$278.30k | 0.0099% $ 563.5k | |
| Independent Lead Director | 8yrs | US$317.48k | 0.016% $ 930.9k | |
| Independent Director | 5yrs | US$302.48k | 0.011% $ 628.1k | |
| Independent Director | 13.9yrs | US$279.98k | 0.0037% $ 210.9k | |
| Independent Director | 2yrs | US$269.98k | 0.0060% $ 341.3k | |
| Independent Director | 6yrs | US$282.48k | 0.013% $ 723.9k |
5.0yrs
평균 재임 기간
59.5yo
평균 나이
경험이 풍부한 이사회: NOVT의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/13 05:02 |
| 종가 | 2026/05/13 00:00 |
| 수익 | 2026/04/03 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Novanta Inc.는 8명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Robert Mason | Baird |
| Quinn Fredrickson | Baird |
| Andrew Buscaglia | Berenberg |